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Effective tolerogenic intervention in Rheumatoid Arthritis (RA) will rely upon understanding
the evolution of articular antigen specific CD4 T cell responses. TCR clonality of
endogenous CD4 T cell infiltrates in early inflammatory arthritis was assessed to
monitor evolution of the TCR repertoire in the inflamed joint and associated lymph node
(LN). Mouse models of antigen-induced breach of self-tolerance and chronic polyarthritis
were used to recapitulate early and late phases of RA. The infiltrating endogenous, antigen
experienced CD4 T cells in inflamed joints and LNs were analysed using flow cytometry
and TCRb sequencing. TCR repertoires from inflamed late phase LNs displayed increased
clonality and diversity compared to early phase LNs, while inflamed joints remained similar
with time. Repertoires from late phase LNs accumulated clones with a diverse range of
TRBV genes, while inflamed joints at both phases contained clones expressing similar
TRBV genes. Repertoires from LNs and joints at the late phase displayed reduced CDR3b
sequence overlap compared to the early disease phase, however the most abundant
clones in LNs accumulate in the joint at the later phase. The results indicate CD4 T cell
repertoire clonality and diversity broadens with progression of inflammatory arthritis and is
first reflected in LNs before mirroring in the joint. These observations imply that antigen
specific tolerogenic therapies could be more effective if targeted at earlier phases of
disease when CD4 T cell clonality is least diverse.
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Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterised by synovial
inflammation and cartilage and bone erosion, causing progressive loss of joint function (1). Antigen
presentation and CD4 T activation mechanisms have been shown to play a role in the pathogenesis
of RA. This is evidenced by genetic association studies in RA patients showing strong associations oforg April 2021 | Volume 12 | Article 6698561
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PTPN22 and CTLA-4, and loci associated with signal
transduction such as STAT4 (2–7). Moreover, the successes of
therapeutics in modulating T cell activation, such as the use of
Abatacept, reinforce the importance of CD4 T cells in
propagating the disease (8). As such, there has been increasing
interest in targeting pathogenic autoreactive CD4 T cells using
antigen specific tolerogenic therapies as this line of therapy aims
to re-establish tolerance and provide long-lasting remission,
while retaining protective immunity against pathogens.
However, targeting autoreactive CD4 T cells has proven
difficult in RA, due to the broad range of antigens implicated
in disease, lack of a clear cellular hierarchy of disease drivers, and
also patient to patient variation (9–13). Moreover, it is unknown
at what stages of the disease these autoreactive responses develop
nor the location in which these responses are primed, thus
hampering the development of effective tolerogenic therapies.
Antigen specific responses can be identified by detecting
expanded clonal T cell populations. Indeed, oligoclonal CD4 T
cell responses and skewed TCR repertoires have been reported in
arthritic joints (14–17). More recently, analysis of CD4 T cell
behaviour was shown to reflect antigen recognition in inflamed
joints at the early stages of disease (18), suggesting that antigen
specific CD4 T cell responses may perpetuate and drive
progression of RA. However, the development of antigen
specific responses and their evolution with the progression of
RA is poorly understood. Investigating the evolution TCR
clonality of antigen experienced CD4 T cells in RA will
provide insight on how antigen specific responses evolve with
disease progression. This will inform the development of more
effective tolerogenic therapies by indicating the range of clones
that would need to be targeted and the disease stage at which
these therapies are most likely to be effective. In this study, we
employed breach of self-tolerance models of antigen induced
inflammatory arthritis (19, 20) and chronic polyarthritis (21) in
which autoreactive responses develop. These models also
recapitulate the early and later stages of the disease – hereafter
named the early and late phases respectively. TCRb sequencing
was used to monitor the evolution of antigen specific endogenous
CD4 T cell responses in inflamed joints and their associated
draining lymph nodes.METHODS
Animals
Male and female C57BL/6 mice aged 7-12 weeks were purchased
from Envigo (UK), and used as adoptive transfer recipients. OT-
II TCR transgenic mice (22) were bred inhouse. All mice were
maintained at the University of Glasgow’s central research
facility and housed under standard housing conditions
specified by the UK Home Office.Induction of Inflammatory Arthritis
“Early” antigen induced inflammatory arthritis was conducted as
previously described (19, 20). Briefly, 2-3x106 Th1 polarised OT-Frontiers in Immunology | www.frontiersin.org 2II transgenic T cells were transferred i.v. into C57BL/6 recipients.
Recipients were immunised with 100μL of 1μg/mL of OVA
protein (Worthington Biochemicals) in Freund’s complete
adjuvant (CFA) (Sigma-Aldrich) subcutaneously after 24
hours. Ten days later, mice were given a periarticular injection
in footpads with 50μL of 100μg of heat aggregated OVA (HAO)
or PBS as a control. Mice were sacrificed four days later and cells
were isolated from joint tissue and draining popliteal lymph
nodes (pLN).
The “late” model antigen induced inflammatory arthritis was
modified from a model of chronic polyarthritis (21). 30 days after
HAO administration described above, mice were given a second
periarticular injection of 100μg of HAO in incomplete Freund’s
adjuvant (IFA) (Sigma-Aldrich) or IFA alone as a control. Mice
were sacrificed 17 days later and cells were isolated from joint
tissues and pLNs.
Isolation of Cells From Tissues
Cells from mouse joints and pLNs were isolated as previously
described (18). Briefly, ankle joints were teased apart and shaken
at 110 rpm at 37°C for 25 minutes with 2.68mg/mL collagenase
D (Roche) in RPMI 1640 (Gibco, Thermo Fisher Scientific). Joint
tissue was then homogenised using a gentleMACS Dissociator
(Miltenyi Biotech) then strained to obtain single cell suspensions.
PLNs were forced through Nitex mesh (Cadisch Precision
Meshes) to obtain single cell suspensions. Samples were
washed and stained for flow cytometry. Joint and pLN samples
were analysed separately. Joint samples and pLN samples were
pooled per mouse.
Flow Cytometry
Cells were stained for flow cytometry as described previously
(18). The following antibodies were used: anti-CD4 (clone
GK1.5), anti-CD44 (clone IM7), anti-CD45 (clone 30-F11),
anti-CD45.1 (clone A20). Data was analysed using FlowJo v10
software (Treestar, Oregon USA).
TCRb Sequencing
The data for this study have been deposited in the European
Nucleotide Archive (ENA) at EMBL-EBI under the accession
number PRJEB40509 (https://www.ebi.ac.uk/ena/browser/view/
PRJEB40509). CDR3b sequencing was performed by iRepertoire
Inc. (Huntsville, AL, USA) on total RNA collected from sorted
antigen experienced endogenous CD4 T cells (CD4+, C45.1-,
CD44hi). CD4+, CD45.1-, CD44hi were sorted from joint and
pLN samples using the BD Aria III FACS sorter (BD
Biosciences). Samples were collected separately from individual
mice in lysis buffer (Purelink RNA micro kit, Thermofisher) +
1% b-mercaptoethanol (Sigma-Aldrich) and lysed using 29G
insulin syringes (VWR). Lysed cells were then stored at -80°C
prior to RNA purification. Total RNA was purified using the
Purelink RNA micro kit (Thermo Fisher Scientific) as per
manufacturer’s instructions and quality assessed by measuring
A260/280 using a Nanodrop 1000 spectrophotometer (Thermo
Fisher Scientific). Barcoded libraries were prepared per sample
using barcoded primers covering the V-J TCR region, then
amplified, pooled, and sequenced using the Illumina MiSeqApril 2021 | Volume 12 | Article 669856
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analysis was performed by iRepertoire. Sequencing data was
also prepared for analysis using MiXCR developed by Bolotin
et al. (23) and analysed using tcR developed by Nazarov et al.
(24) in the R statistical software frame work (R version 3.4.3).
Calculation of the D50 Diversity Index (DI)
Diversity was calculated using iRepertoire’s data analysis guide.
For samples where the number of unique CDR3b
sequences ≥10,000:
DI ¼ rank of  unique CDR3b sequence where 50%  of  the top
 10;000 total reads f alls   100=10;000
For samples where the number of unique CDR3b
sequences <10,000:
DI  =  rank of  unique CDR3b sequence where 50%  of  the to
tal reads falls   100=no :  of  unique CDR3b sequences
Calculation of Repertoire Overlap
The number of shared CDR3b amino acid sequences is
represented as a normalised overlap index taking into
consideration the size of the repertoires being compared. The
normalised overlap index was calculated using the tcR R package
(24) using the following calculation:




Data is shown as mean ± SD. Specific test and significance levels
are stated in respective figure legends. Statistical analyses were
performed using GraphPad Prism version 7 (GraphPad Inc, CA,
USA) or using the R statistical software framework (R
version 3.4.3).RESULTS
Induction of Inflammatory Arthritis Results
in Local Accumulation of Endogenous
Antigen Experienced CD4 T Cells at Both
the Early and Late Phases
Induction of the breach of tolerance model of inflammatory
arthritis requires the transfer of Th1 polarised ovalbumin (OVA)
specific OT-II cells and subsequent immunisations with OVA
and heat aggregated OVA (HAO) as outlined in Figure 1A. This
results in the influx of the transferred OT-II cells and
endogenous CD4 T cells of varying antigen specificities,
indicated by the range of expressed TCRb variable genes
(TRBV) (18). Assessing the evolution of TCR clonality of the
endogenous CD4 T cell population requires the accurate
identification of these cells in joints and popliteal lymph nodes
(pLN), being distinguishable from the transferred OT-IIs by
expression of the congenic marker CD45.1 (Supplementary
Figures 1 and 2). Endogenous CD4 T cells were present at a
significantly higher number than the transferred OT-II cells in
inflamed pLNs and joints at both the early and late phasesFrontiers in Immunology | www.frontiersin.org 3(Figure 1B). A significant number of endogenous CD4 T cells at
the early phase also displayed an antigen experienced phenotype,
indicated by increased CD44 expression, after induction of
inflammatory arthritis with HAO (Figure 1C), and were
previously shown to produce TNFa and IFNg following ex-
vivo stimulation with PMA/ionomycin (18). The number of
endogenous CD4, CD44hi cells was also increased at the late
phase in inflamed joints (Figure 1C).
Accumulation of Expanded Clones and
Observed Clonality and Diversity of CD4
T Cell Repertoires Is Antigen Driven
To investigate the evolution of CD4 TCR clonality in this model
of inflammatory arthritis, endogenous antigen experienced CD4
T cells i.e. excluding the transferred OT-II cells, were sorted from
pLNs and joints of individual mice at both early and late phases.
Total RNA was then isolated from the endogenous CD4 T cells
and used to sequence the CDR3b region of the TCR, the most
variable region of the TCR critical in recognition of specific
peptide sequences (25, 26). Repertoires were then characterised
by examining the number of unique CDR3b sequences and
evaluating the degree expanded clones contributed to the
overall antigen experienced repertoire. From this, the clonality
and diversity of the CD4 T cell repertoire can be determined. In
this study, clonality is defined by the number of unique CDR3b
sequences found in the population, and diversity—represented
by the Diversity Index (DI) (see Methods)—represents the
relative contribution of each unique CDR3b sequence, or
clone, to the population. Thus, a repertoire with a larger
number unique CDR3b sequences, and therefore clones, would
be described to have high clonality. This repertoire would also
display high diversity and have a high DI value if the number of
cells contributing to different clonal populations are more evenly
distributed. Conversely, the repertoire would be described to
have low diversity and have a low DI value if the repertoire is
mainly comprised of a few clones present in high frequencies
relative to the total number of clones. Due to the low recovery of
antigen experienced endogenous CD4 T cells isolated from
control pLNs and joints at the early phase, cells from control
pLNs or joints needed to be pooled prior to sequencing. Pooling
samples changes the composition of the repertoire and affects T
cell repertoire diversity, so comparisons of control CD4 T cell
populations were made against pooled data from inflamed joint
and pLN samples at the early phase (Figures 2A, B).
Clonality of the endogenous CD4 T cell repertoire from
inflamed pLNs at the early phase and controls were comparable
(4181 unique CDR3b sequences in the inflamed pLN repertoire vs
4347 in the PBS pLN repertoire). However, the repertoire from the
inflamed pLN showed a reduced diversity compared with the
control pLN sample (6.4 vs 16.3 respectively). Endogenous CD4
T cell repertoires from inflamed joints displayed higher clonality
than controls (4549 vs 885). Despite this, the diversity of the
repertoire in the inflamed joint was relatively low compared to
the PBS joint (0.72 vs 9.3 respectively). These data therefore
demonstrate that accumulation of clones can be detected at the
early phases of the disease in both inflamed pLNs and joints.April 2021 | Volume 12 | Article 669856
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in the absence of their cognate antigen has been demonstrated in
this model (18) and in RA patients (27–29) which may be a result
of a chronic inflammatory environment (30, 31). To address
whether the accumulation of clones is antigen driven rather than
a result of non-antigen induced inflammation, the antigen
experienced repertoires of pLNs and joints at the late phase
were compared to repertoires isolated from mice challenged with
IFA alone (Figure 3A), where inflammation is induced without
the presence of antigen. No significant difference was found
between the contribution of the top 10 most expanded clones to
the repertoires of inflamed pLNs at the late phase and IFA
controls (data not shown) nor when comparing the contribution
of clones occurring at the lowest frequency (Figure 3B). The
number of clones occurring at a frequency of 2 or more were also
compared between inflamed and IFA pLN samples as this was
the median frequency of clones found in the PBS pLN sampleFrontiers in Immunology | www.frontiersin.org 4(data not shown). Thus, clonal populations found at higher than
this frequency are assumed to have accumulated due to the
presence of antigen. No clonal accumulation was detected
between inflamed pLNs at the late phase and IFA controls
(p value 0.32 Welch two sample t-test). Moreover, repertoires
from inflamed pLNs at the late phase and IFA displayed
comparable levels of clonality and diversity (Figures 3C, D).
In late phase arthritic joints, the top 10 highly expanded
clones constituted approximately 41% of the overall repertoire
compared to joint IFA controls, where the top clones only
comprised an average of 29% of the entire repertoire (Figures
3E, F). No difference in clonality was detected between
repertoires from inflamed joints and IFA controls (Figure 3G),
but inflamed joints have reduced clonal diversity compared to
IFA controls (Figure 3H). This would suggest that antigen
driven accumulation of expanded clones in inflamed joints can
also be observed at the late phase.A
B
C
FIGURE 1 | Outline of model phases and number of endogenous, OT-II, and endogenous antigen experienced CD4 T cells at both phases. (A) Illustration of early
and late phases of inflammatory arthritis. (B) Number of endogenous CD4 T cells (CD4+, CD45+, CD45.1-) and OT-II T cells (CD4+, CD45+, CD45.1+) from pLNs
and joints of mice undergoing inflammatory arthritis at the early and late phases and respective controls. (C) Number of antigen experienced endogenous CD4 T
cells (CD4+, CD45+, CD45.1-, CD44hi) from pLNs and joints of mice undergoing inflammatory arthritis at the early and late phases and respective controls. Data is
representative of mean ± SD with each point representing individual experimental mice. Data represents three independent experiments for the early phase and two
independent experiments for the late phase with n=5 for each experiment. Groups were compared using 2-way ANOVA and Student’s t-tests. Stars represent the
following p-values: *<0.05, **<0.01; ***<0.001; ****<0.0001; ns, not significant. HAO, heat-aggregated OVA; IFA, incomplete Freund’s adjuvant.April 2021 | Volume 12 | Article 669856
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CD4 T Cell Repertoire Displays Disparity in
Clonal Diversity Between Inflamed pLNs
and Joints With Time
Antigen experienced endogenous CD4 T cell repertoires
from pLNs and joints were compared between the early and
late phases to investigate how CD4 TCR clonality evolves
with disease progression (Figures 4A, E). When comparing
inflamed pLNs at the early and late phases, the top 10 most
expanded clones contributed approximately 18% to the overall
antigen experienced repertoire of inflamed pLNs at the early
phase compared to only 2% at the late phase (Figures 4A, B).
When comparing clonality and diversity, repertoires from pLNs
isolated at the late phase displayed increased clonality and
diversity compared with their early counterparts (Figures 4C,
D) and comprised mainly of low abundance clones. In contrast
to the pLNs, antigen experienced CD4 T cell repertoires isolated
from inflamed joints at the early and late phases were similar; the
top 10 most expanded clones dominated the repertoires and
comprised on average 46% and 41% of the overall populations
(Figures 4E, F). Furthermore, no differences were observed
between the clonality and diversity of the repertoires at the
early and late phases (Figures 4G, H) and repertoire diversityFrontiers in Immunology | www.frontiersin.org 5overall was low in the joint at both phases. Together, these data
highlight the disparity in repertoire composition between pLNs
and joints at the early and late phases, namely that pLNs at the
late phase displayed high repertoire clonality and diversity
compared to their early counterparts and also compared to
inflamed joints at the same phase.
Disparity in Clonality of the Antigen
Experienced Endogenous CD4 T Cell
Repertoires Is Attributed to Accumulation
of Clones With Different TCRb Variable
(TRBV) Genes
Characterisation of the antigen experienced CD4 T cell
repertoires from pLNs and joints at the early and late phases
provided useful information on the overall distribution of clones
in these repertoires. However, this does not provide any insight
on the TCR sequence of these clones, nor on whether these
clones have similar or different TCR sequences between the two
sites. Moreover, no insight is gained on whether the clonal
composition of the antigen experienced repertoires in these
two sites change over time. To address this, a PCA analysis
was performed on inflamed pLNs and joints at both the early and
late phases on the basis of TRBV gene use (Figure 5A).A
B
FIGURE 2 | Characterisation of antigen experienced endogenous CD4 T cell repertoires from inflamed pLNs and joints and PBS controls at the early phase.
Proportion of the top 10 most frequently occurring clones, followed by the next 25, 500, 3000, 10,000, and 100,000 most frequent clones contributing to the
endogenous antigen experienced CD4+ T cell repertoire in (A) pooled inflamed pLNs and joint samples at the early phase (HAO) and pooled PBS controls.
(B) Descriptive statistics of pooled inflamed pLN and joint samples at the early phase and their PBS controls indicating endogenous CD4 T cell number, clonality,
and diversity. Data represents 1 experiment with pooled samples from 3 mice for the PBS sample and 5 mice for the inflamed (HAO) sample.April 2021 | Volume 12 | Article 669856





FIGURE 3 | Characterisation of antigen experienced endogenous CD4 T cell repertoires from inflamed pLNs and joints and IFA controls at the late phase.
Proportion of the top 10 most frequently occurring clones, followed by the next 25, 500, 3000, 10,000, and 100,000 most frequent clones contributing to the
endogenous antigen experienced CD4+ T cell repertoire in (A) inflamed pLNs, and (E) inflamed joints at the late phase (HAO+IFA) and IFA only controls.
(B) Proportion of the least frequently occurring clones in inflamed pLNs at the late phase and IFA controls. (F) Percentage contribution of the top 10 most frequently
occurring clones in inflamed joints at the late phase and IFA controls. (C, G) clonality, represented as the number of unique CDR3b DNA sequences, in (C) inflamed
pLNs and IFA controls, and (G) inflamed joints and IFA controls at the late phase. (D, H) diversity indices of (D) inflamed pLNs and IFA controls, and (H) inflamed
joints and IFA controls at the late phase. Data is representative of mean ± SD with each point representing individual experimental mice. Data represents 1
experiment with n=5 for the inflamed group and n=3 for the control group. Groups were compared using unpaired Student’s t-test. Stars represent the following
p values: *<0.05; ns, not significant.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6698566





FIGURE 4 | Characterisation of antigen experienced endogenous CD4 T cell repertoires in inflamed pLNs and joints at the early and late phases. Proportion of the
top 10 most frequently occurring clones, followed by the next 25, 500, 3000, 10,000, and 100,000 most frequent clones contributing to the endogenous antigen
experienced CD4+ T cell repertoire in (A) inflamed pLNs at the early and late phases, and (E) inflamed joints at the early and late phases. (B, F) percentage
contribution of the top 10 most frequently occurring clones in (B) inflamed pLNs and (F) inflamed joints at the early and late phases. (C, G) clonality, represented as
the number of unique CDR3b DNA sequences, in (C) inflamed pLNs, and (G) inflamed joints at the early and late phases. (D, H) diversity indices of (D) inflamed
pLNs, and (H) inflamed joints at the early and late phases. Data is representative of mean ± SD with each point representing individual experimental mice. Data
represents 1 experiment with n=5 for both the early and late phase groups. Groups were compared using unpaired Student’s t-test. Stars represent the following
p values: ***<0.001; ****<0.0001; ns, not significant.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6698567
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displayed the largest range in TRBV gene use, while inflamed
pLNs and joints at the early phase as well as inflamed joints at the
late phase grouped together in terms of TRBV gene expression.
Indeed, when quantifying these differences, inflamed pLNs at the
late phase had significantly increased presence of TRBV genes 1,
2, 3, 5, and 19, while TRBV genes 12-1, 12-2, and 13-1 were
present in the highest frequencies in inflamed pLNs at the early
phase (Figure 5B). These differences are also due to changes in
TRBV gene use and not in TRBJ genes (Figure 5C). Interestingly,
the PCA analysis also highlighted inter-sample differences in
TRBV gene use in inflamed pLNs at the late phase.
Accumulation of clones expressing different TRBV genes in
inflamed pLNs at the late phase suggests changes in antigen
specific responses with time and also between inflamed pLNs andFrontiers in Immunology | www.frontiersin.org 8their associated tissues. Moreover, these changes in antigen
specific responses also differ between individual animals
with time.
Antigen Associated Changes in the
Inflamed pLN May Predict the Changes in
Antigen Specificities and Clonality of the
CD4 T Cell Repertoire in Inflamed Joints
To assess whether changes in CD4 TCR clonality reflected
changes antigen specificities, the degree of CDR3b amino acid
sequence overlap between the antigen specific CD4 T cell
repertoires was investigated. Comparing the repertoire overlap
between inflamed pLNs and joints at both the early and late
phases allowed us to monitor clonal dynamics between these two
sites with the progression of inflammatory arthritis. The numberA
B
C
FIGURE 5 | Range of TRBV genes expressed in antigen experienced endogenous CD4 T cell repertoires of inflamed pLNs and joints at the early and late phases.
(A) PCA plot of TRBV gene frequency in repertoires of inflamed pLNs and joints at the early and late phases. Frequency of (B) TRBV gene expression, and (C) TRBJ
gene expression in inflamed pLNs at the early and late phases. Graphs represent 1 experiment with n=5 for both the early and late inflamed groups. Groups were
compared using ordinary 2-way ANOVA with Sidak’s multiple comparisons test. Data presented as mean ± SD. Stars represent the following p values: *<0.05;
**<0.01; ***<0.001; ****<0.0001; ns, not significant.April 2021 | Volume 12 | Article 669856
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the normalised overlap index (see methods) and this decreased
between the inflamed pLN and its joint with the progression of
inflammatory arthritis (Figures 6A, B). CDR3b sequence
overlap decreased significantly between samples when
comparing repertoires from inflamed pLN samples at the early
phase to inflamed pLNs at the late phase (Supplementary Figure
3A), while the degree of CDR3b amino acid sequence overlap
remained unchanged between repertoires from inflamed joints at
the early and late phases (Supplementary Figure 3B). These
observations confirm the observed changes in TRBV gene use
and also imply changes in antigen specific responses in pLNs,
which progress towards polyclonality with disease progression.
Correlation analysis revealed that the top 10 most expanded
clones in the inflamed joint at the late phase correlated
significantly with the most expanded clones in the inflamed
pLNs at the same phase (Figure 6D). Furthermore, the 10 most
expanded clones in inflamed joints at the early phase and those
from IFA controls did not correlate with the most highly
expanded clones in their respective pLNs (Figures 6C, E).
Moreover, the 10 most expanded clones in inflamed joints at
the early phase were not all present in their respective pLNs
(Supplementary Table 1), but the top 10 expanded clones in
inflamed joints at the late phase were all present in inflamed
pLNs at the same phase (Supplementary Table 2). These results
indicate that despite pLNs progressing towards polyclonality
with the development of disease, the most highly expanded
antigen experienced clones accumulate in the inflamed joint.
Thus repertoire clonality in the pLN may eventually be mirrored
in the inflamed joint with disease progression.DISCUSSION
Characterising CD4 TCR clonality has been used to monitor
progression of disease states in cases of infection (32) and
autoimmunity (33, 34), including RA (15, 35–38). Although
CD4 T cell clonality has been determined in RA patients
at different stages of the disease (15, 17), the development
of antigen specific responses from very early, pre-clinical
stages to a more established disease stage remains unknown.
Understanding this is important to develop effective tolerogenic
therapies as the range of CD4 T cell clones to target and the
timepoint this therapy will have the greatest impact can be
determined. Thus, we investigated the evolution of CD4 TCR
clonality by sequencing CDR3b regions of antigen experienced
endogenous CD4 T cells isolated from pLNs and joints at early
and late phases of breach of self-tolerance models of
inflammatory arthritis.
Induction of inflammatory arthritis resulted in the
accumulation of endogenous CD4 T cells displaying an antigen
experienced phenotype. This population has been previously
shown to produce TNFa and IFNg and also harbour
autoreactive clones capable of causing bone and cartilage
degradation (18–21, 39, 40). CDR3b analysis of this this
population revealed that TCR repertoires from inflamed jointsFrontiers in Immunology | www.frontiersin.org 9at both the early and late phases displayed low clonality and
diversity and were dominated by few clones present at high
frequencies. In contrast, pLNs at the late phase displayed higher
clonality and diversity compared with their counterparts at the
early phase and were mainly composed of a large number of
clones that were present at low frequencies. This indicates that
pLNs become more polyclonal with the progression of
inflammatory arthritis. Moreover, correlation of the most
frequently occurring clones in the inflamed joint at the late
phase with the most frequently occurring clones in the inflamed
pLN at the same phase indicates that this polyclonality occurs in
the pLNs before possibly being reflected in inflamed joints.
Addressing whether the joint endogenous CD4 T cell
repertoire does in fact become more polyclonal with more
established disease was not possible due to the self-resolving
nature of the model. However, the observations reported here are
in line with clinical studies that have reported increased T cell
clonality and diversity in inflamed joints of patients with
established RA compared to early RA patients (15, 41).
Uncovering the underlying factors contributing to CD4 T cell
repertoire polyclonality was beyond the scope of the study.
However, PCA analysis of TRBV genes of repertoires isolated
from inflamed pLNs and joints at the early and late phases
highlighted the expanded range of TRBV genes present in
repertoires of pLNs at the late phase, indicating a possible
change in antigen specific responses with the progression of
inflammatory arthritis as a reason for polyclonality. One theory
for changes in antigen driven responses could be due to the
release of neo-antigens resulting from continued joint damage
and/or epitope spreading, a phenomenon observed in RA
patients (42, 43). In the model itself however, polyclonality can
also be explained by the re-establishment of lymphatic
recirculation. Given that the observations reported were
exclusively on the antigen experienced CD4 T cell population,
re-establishment of lymphatic recirculation is an unlikely
explanation for the changes in the repertoire clonality and
diversity observed. Moreover, the 10 most abundant antigen
experienced clones correlate significantly between inflamed
pLNs and joints at the late phase and not in IFA controls.
Inflamed joints were also shown to have reduced diversity in the
antigen experienced repertoire compared to joint IFA controls.
By taking these observations together, one can deduce that
changes in pLN repertoire clonality, diversity, and TRBV genes
is in fact antigen driven.
CDR3b amino acid sequence overlap analysis between
repertoires isolated from pLNs and joints at early and late
phases of inflammatory arthritis highlighted that fewer clones
are shared between pLNs and joints at the late phase compared to
the early phase. This indicates that antigen specific responses
differ between these sites with time, driven by changes in
clonality, diversity, and clones with different TRBV genes in
the pLN. Moreover, the reduced clonal overlap at the late phase
highlight the fact that inflamed pLNs and joints display different
antigen specific responses at the same phase. The disparity may
highlight a timepoint in the disease where pathogenic clones
have not yet migrated to the joint to perform their effectorApril 2021 | Volume 12 | Article 669856





FIGURE 6 | Degree of CDR3b amino acid sequence overlap and correlation of most abundant clones between inflamed pLNs and joints at the early and late
phases. (A) Heatmaps of normalised number of CDR3b amino acid sequences (see methods) between inflamed pLNs and joints at the early (left) and late (right)
phases. (B) Graph representing the intersects (diagonal) of (A) representing CDR3b sequence overlap between inflamed pLNs and joint within the same animal.
(C–E) Correlation of the top 10 ranked clones in joints with their rank in respective pLN samples. The rank of each of the top 10 clones in (C) inflamed joint at the
early phase, (D) inflamed joint at the late phase, and (E) IFA control joint samples were plotted against the rank of that clone in respective pLN samples. Data is
representative of one experiment with n=5 for the early and late phase inflamed groups and n=3 for controls. Graph in (B) is representative of mean ± SD with each
point representing individual experimental mice. * represents p<0.05. In C-E correlations (r) were calculated using Spearman’s correlation after testing for normality of
the data using the D’Agostino-Pearson test. p represents the p value.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 66985610
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intervention. As such, analysis of CD4 T cell clonality between
arthritic lymph nodes and joints could serve as a biomarker for
disease state and be a method to stratify different RA patients to
better modulate the disease. Assessment of clonality can be
performed in conjunction with existing methods used to
evaluate changes in arthritic lymph nodes with disease
progression, such as using lymph node biopsies to evaluate
changes in cellular composition and function at different
disease stages (44, 45). Furthermore, as the trend towards
polyclonality is likely associated with antigen specific
responses, clonal compositions can serve as a biomarker to
assess the therapeutic impact of RA tolerogenic therapies (46,
47). Indeed, effective RA therapeutics have been shown to reduce
clonal expansion of CD4 T cells (36). In addition, understanding
the clonal landscape with disease development can inform when
such therapies could be most effective. For instance, antigen
specific therapies may be more effective when the CD4 T cell
clonality and diversity is restricted.
In conclusion, these data outline the evolution of clonal
dynamics between inflamed pLNs and their joints with the
progression of inflammatory arthritis in that CD4 TCR
clonality, begin by being similar between the two sites then
change in the pLN with the progression of the disease before
potentially being mirrored in the joint in time. These
observations suggest that assessment of CD4 T cell clonality
can serve as a biomarker for disease progression, at least in
subtypes with significant lymphocyte infiltrate in the synovium,
and assess the efficacy of RA therapeutics. Specifically, evaluation
of changes in CD4 T cell clonality can be used to assess effective
antigen specific tolerogenic therapies in RA and also inform
timing of such therapies for maximum therapeutic impact.DATA AVAILABILITY STATEMENT
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Supplementary Figure 1 | Gating strategy to identify antigen experienced
endogenous CD4 T cells from pLNs and joints. Representative flow cytometry plots
identifying antigen experienced endogenous CD4 T cells (CD4+, CD45+, C45.1-,
CD44hi) from (A) inflamed pLNs, and (B) inflamed joints at the early phase of mice
undergoing inflammatory arthritis.
Supplementary Figure 2 | Representative flow cytometry plots identifying
antigen experienced endogenous CD4 T from (A) pLN, and (B) joint PBS controls at
the early phase, (C) pLN, and (D) joints IFA controls at the late phase, and (E)
inflamed pLN, and (F) inflamed joints at the late phase.
Supplementary Figure 3 | Degree of CDR3b amino acid sequence overlap
between inflamed pLN and inflamed joint samples at the early and late phases.
Heatmaps of normalised number of CDR3b amino acid sequences between (A)
inflamed pLNs, and (C) inflamed joints at the early and late phases. (B and D)
Normalised overlap values between (B) inflamed pLN samples, and (D) inflamed
joint samples at the early and late phases. Data is representative of mean ± SD with
each point representing individual experimental mice. Data represents 1 experiment
with n=5 for both the early and late inflamed groups. Groups were compared using
unpaired Student’s t-test. Stars represent the following p values: ** <0.01; ns: not
significant.April 2021 | Volume 12 | Article 669856
Al Khabouri et al. Clonal T Cell Responses Inflammatory ArthritisSupplementary Table 1 | The top 10 frequently occurring clones inflamed joint
samples at the early phase ranked in terms of frequency in respective pLNs. The top
10 frequently occurring clones in the antigen experienced CD4+ T cell repertoire
were found in each of the inflamed joint samples at the early phase and searched for
in respective pLN samples. The CDR3b amino acid sequence, associated TRBV
gene, read count, and rank of the clone in the pLN sample was obtained. The rank
of each of the top 10 clones in the joint are also included in the table. Data is
representative of 1 experiment with n=5.Frontiers in Immunology | www.frontiersin.org 12Supplementary Table 2 | The top 10 frequently occurring clones inflamed joint
samples at the late phase ranked in terms of frequency in respective pLNs. The top
10 frequently occurring clones in the antigen experienced CD4+ T cell repertoire
were found in each of the inflamed joint samples at the late phase and searched for
in respective pLN samples. The CDR3b amino acid sequence, associated TRBV
gene, read count, and rank of the clone in the pLN sample was obtained. The rank
of each of the top 10 clones in the joint are also included in the table. Data is
representative of 1 experiment with n=5.REFERENCES
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44. Rodrıǵuez-Carrio J, Hähnlein JS, Ramwadhdoebe TH, Semmelink JF, Choi IY,
van Lienden KP, et al. Brief Report: Altered Innate Lymphoid Cell Subsets in
Human Lymph Node Biopsy Specimens Obtained During the At-Risk and
Earliest Phases of Rheumatoid Arthritis. Arthritis Rheumatol Hoboken NJ
(2017) 69:70–6. doi: 10.1002/art.39811
45. Ramwadhdoebe TH, Hähnlein J, Maijer KI, van Boven LJ, Gerlag DM, Tak
PP, et al. Lymph Node Biopsy Analysis Reveals an Altered Immunoregulatory
Balance Already During the At-Risk Phase of Autoantibody Positive
Rheumatoid Arthritis. Eur J Immunol (2016) 46:2812–21. doi: 10.1002/
eji.201646393
46. Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, et al.
Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory
Arthritis. Ann Rheum Dis (2017) 76:227–34. doi: 10.1136/annrheumdis-2015-
208456
47. Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, et al.
Citrullinated Peptide Dendritic Cell Immunotherapy in HLA Risk Genotype-
Positive Rheumatoid Arthritis Patients. Sci Transl Med (2015) 7:290ra87.
doi: 10.1126/scitranslmed.aaa9301
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.Citation: Al Khabouri S, Benson RA, Prendergast CT, Gray JI, Otto TD, Brewer JM
and Garside P (2021) TCRb Sequencing Reveals Spatial and Temporal Evolution of
Clonal CD4 T Cell Responses in a Breach of Tolerance Model of Inflammatory
Arthritis.
Front. Immunol. 12:669856. doi: 10.3389/fimmu.2021.669856
Copyright © 2021 Al Khabouri, Benson, Prendergast, Gray, Otto, Brewer and Garside.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) and the copyright owner(s) are credited and
that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.April 2021 | Volume 12 | Article 669856
